Maspin differential expression patterns as a potential marker for targeted screening of esophageal adenocarcinoma/gastroesophageal junction adenocarcinoma.
Adenocarcinoma
/ metabolism
Barrett Esophagus
/ metabolism
Biomarkers, Tumor
/ metabolism
Case-Control Studies
Disease Progression
Esophageal Neoplasms
/ metabolism
Esophagogastric Junction
/ metabolism
Esophagus
/ metabolism
Humans
Metaplasia
/ metabolism
Precancerous Conditions
/ metabolism
Serpins
/ metabolism
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
12
2018
accepted:
26
03
2019
entrez:
20
4
2019
pubmed:
20
4
2019
medline:
7
1
2020
Statut:
epublish
Résumé
Barrett's esophagus (BE) is a predisposing factor of esophageal adenocarcinoma/gastroesophageal junction adenocarcinoma (ECA/GEJ Aca). BE patients are stratified and subsequently monitored according to the risk of malignant progression by the combination of endoscopy and biopsy. This study is to evaluate the maspin expression patterns as early diagnostic markers of malignancy in BE patients. Immunohistochemistry (IHC) staining was performed on 62 archival core biopsies from 35 patients, including BE without dysplasia (intestinal metaplasia, IM), BE with low grade dysplasia, BE with high grade dysplasia, carcinoma in situ, and well to poorly differentiated ECA/GEJ Aca (PD-ECA/GEJ Aca). The intensity and the subcellular distribution of immunoreactivity were evaluated microscopically. Statistical analysis was performed using the χ2 and Fisher exact tests. The level of epithelial-specific tumor suppressor maspin protein inversely correlated with the progression from IM to PD-ECA/GEJ Aca. Lesions of each pathological grade could be divided into subtypes that exhibited distinct maspin subcellular distribution patterns, including nuclear only (Nuc), combined nuclear and cytoplasmic (Nuc+Cyt), cytoplasmic only (Cyt) and overall negligible (Neg). The Cyt subtype, which was minor in both IM and dysplasia (approximately 10%), was predominant in ECA/GEJ Aca as early as well-differentiated lesions (more than 50%: p = 0.0092). In comparison, nuclear staining of the tumor suppressor TP53 was heterogeneous in dysplasia, and did not correlate with the differentiation grades of ECA/GEJ Aca. The Cyt subtype of maspin expression pattern in core biopsies of BE patients may serve as a molecular marker for early diagnosis of ECA/GEJ Aca.
Identifiants
pubmed: 31002675
doi: 10.1371/journal.pone.0215089
pii: PONE-D-18-34875
pmc: PMC6474598
doi:
Substances chimiques
Biomarkers, Tumor
0
SERPIN-B5
0
Serpins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0215089Subventions
Organisme : NCI NIH HHS
ID : P30 CA022453
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Dig Dis Sci. 2013 Mar;58(3):699-705
pubmed: 23053896
Am J Surg Pathol. 2016 May;40(5):e45-66
pubmed: 26813745
Cancer Res. 2006 Sep 15;66(18):9323-9
pubmed: 16982778
CA Cancer J Clin. 2005 Nov-Dec;55(6):334-51
pubmed: 16282279
Cancer Res. 2017 Sep 15;77(18):5208-5210
pubmed: 28877938
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
World J Gastroenterol. 2016 Dec 21;22(47):10316-10324
pubmed: 28058012
J Biol Chem. 2005 Oct 14;280(41):34985-96
pubmed: 16049007
Clin Breast Cancer. 2002 Oct;3(4):281-7
pubmed: 12425757
Anticancer Res. 2018 May;38(5):3001-3007
pubmed: 29715131
Clin Cancer Res. 2000 Aug;6(8):3153-8
pubmed: 10955797
Nature. 2017 Oct 26;550(7677):529-533
pubmed: 29019984
Hum Pathol. 2001 Apr;32(4):368-78
pubmed: 11331953
Oncotarget. 2017 Aug 11;8(39):66476-66490
pubmed: 29029529
Science. 1994 Jan 28;263(5146):526-9
pubmed: 8290962
Crit Rev Eukaryot Gene Expr. 2012;22(3):249-58
pubmed: 23140166
Br J Cancer. 2016 Aug 9;115(4):403-10
pubmed: 27441494
Mol Cancer Res. 2011 Jun;9(6):733-45
pubmed: 21622623
Int J Surg Pathol. 2010 Oct;18(5):330-7
pubmed: 20444732
Cancer Res. 2006 Apr 15;66(8):4173-81
pubmed: 16618739
Histopathology. 2014 Dec;65(6):757-63
pubmed: 25040445
J Cell Biochem. 2006 Mar 1;97(4):651-60
pubmed: 16329135
Gastroenterology. 2018 May;154(7):1993-2003
pubmed: 29454789
Dig Dis Sci. 2018 Aug;63(8):2059-2069
pubmed: 29766388
Hum Pathol. 1988 Feb;19(2):166-78
pubmed: 3343032
Ann Intern Med. 2012 Dec 4;157(11):808-16
pubmed: 23208168
Am J Gastroenterol. 2008 Mar;103(3):788-97
pubmed: 18341497
Pathobiology. 2012;79(2):107-14
pubmed: 22286087
Lung Cancer. 2006 Jan;51(1):31-9
pubmed: 16159682
Genes Cancer. 2011 Nov;2(11):1009-22
pubmed: 22737267
Curr Pharm Des. 2010 Jun;16(16):1877-81
pubmed: 20337574
Cancer Res. 2017 Feb 15;77(4):886-896
pubmed: 27923833
Oncotarget. 2017 Dec 22;9(3):3996-4019
pubmed: 29423100
JAMA. 2014 Mar 26;311(12):1209-17
pubmed: 24668102
Nat Rev Genet. 2018 Jun;19(6):327
pubmed: 29713013
Am J Gastroenterol. 2000 Dec;95(12):3383-7
pubmed: 11151865
Histopathology. 2009 Apr;54(5):590-7
pubmed: 19309490
Cancer Res. 2015 Sep 15;75(18):3970-9
pubmed: 26208903
Cancer. 1998 Jul 1;83(1):7-18
pubmed: 9655287
Gastrointest Endosc. 2012 Dec;76(6):1087-94
pubmed: 23164510
Ann Surg Oncol. 2007 Feb;14(2):977-91
pubmed: 17122988
J Egypt Natl Canc Inst. 2017 Dec;29(4):177-183
pubmed: 29126758
PLoS One. 2013 Nov 21;8(11):e74502
pubmed: 24278104
J Biol Chem. 2004 Dec 31;279(53):55540-4
pubmed: 15501821
N Engl J Med. 2014 Aug 28;371(9):836-45
pubmed: 25162890
Anal Quant Cytol Histol. 2012 Apr;34(2):72-8
pubmed: 22611762
Gastroenterology. 2012 Aug;143(2):336-46
pubmed: 22537613
Am J Gastroenterol. 2000 Feb;95(2):387-94
pubmed: 10685740